MA34654B1 - Variants silencieux de fc d'anticorps anti-cd40 - Google Patents

Variants silencieux de fc d'anticorps anti-cd40

Info

Publication number
MA34654B1
MA34654B1 MA35885A MA35885A MA34654B1 MA 34654 B1 MA34654 B1 MA 34654B1 MA 35885 A MA35885 A MA 35885A MA 35885 A MA35885 A MA 35885A MA 34654 B1 MA34654 B1 MA 34654B1
Authority
MA
Morocco
Prior art keywords
antibodies
silent variants
silent
variants
transplant
Prior art date
Application number
MA35885A
Other languages
English (en)
Inventor
Christoph Heusser
James Rush
Karen Vincent
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44925566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34654(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34654B1 publication Critical patent/MA34654B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Abstract

La présente invention concerne des variants silencieux de FC d'anticorps anti-CD40 et des compositions et des procédés d'utilisation desdits anticorps pour le traitement de troubles pathologiques, tels que des troubles auto-immuns et inflammatoires et/ou pour la prévention ou la réduction du risque du rejet de greffe dans une transplantation.
MA35885A 2010-11-15 2013-05-07 Variants silencieux de fc d'anticorps anti-cd40 MA34654B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41356710P 2010-11-15 2010-11-15
PCT/EP2011/070058 WO2012065950A1 (fr) 2010-11-15 2011-11-14 Variants silencieux de fc d'anticorps anti-cd40

Publications (1)

Publication Number Publication Date
MA34654B1 true MA34654B1 (fr) 2013-11-02

Family

ID=44925566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35885A MA34654B1 (fr) 2010-11-15 2013-05-07 Variants silencieux de fc d'anticorps anti-cd40

Country Status (38)

Country Link
US (7) US8828396B2 (fr)
EP (4) EP3502138B9 (fr)
JP (1) JP5782132B2 (fr)
KR (1) KR101632775B1 (fr)
CN (2) CN103209996B (fr)
AR (2) AR083847A1 (fr)
AU (1) AU2011331288B2 (fr)
BR (1) BR112013011644B1 (fr)
CA (1) CA2815921C (fr)
CL (1) CL2013001124A1 (fr)
CO (1) CO6801629A2 (fr)
CR (1) CR20130222A (fr)
CU (1) CU24057B1 (fr)
CY (1) CY1119097T1 (fr)
DK (2) DK3502138T3 (fr)
EA (1) EA026133B1 (fr)
ES (2) ES2633817T3 (fr)
GT (1) GT201300128A (fr)
HR (2) HRP20220413T1 (fr)
HU (2) HUE034203T2 (fr)
IL (1) IL225719A (fr)
JO (1) JO3266B1 (fr)
LT (2) LT2640749T (fr)
MA (1) MA34654B1 (fr)
MX (1) MX336633B (fr)
MY (1) MY159316A (fr)
NZ (1) NZ609549A (fr)
PE (1) PE20140979A1 (fr)
PL (2) PL2640749T3 (fr)
PT (2) PT3502138T (fr)
RS (2) RS56153B1 (fr)
SG (1) SG189928A1 (fr)
SI (2) SI3502138T1 (fr)
TW (2) TWI608016B (fr)
UA (1) UA112417C2 (fr)
UY (2) UY33728A (fr)
WO (1) WO2012065950A1 (fr)
ZA (1) ZA201302532B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP2676677B1 (fr) * 2011-02-17 2019-05-22 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique d'anticorps anti-cd40 très concentrée
CA3122934A1 (fr) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Proteine de fusion comprenant un fragment de cd40 et methode de production
CN106977604A (zh) 2011-04-21 2017-07-25 百时美施贵宝公司 拮抗cd40之抗体多肽
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
JP6163158B2 (ja) 2011-10-13 2017-07-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ４０ｌに拮抗する抗体ポリペプチド
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
WO2015134988A1 (fr) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
WO2016024195A1 (fr) 2014-08-12 2016-02-18 Novartis Ag Conjugués médicament-anticorps anti-cdh6
EP3736294A3 (fr) 2014-10-10 2021-02-17 Innate Pharma Blocage de cd73
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3081942A1 (fr) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Liquide de transmission de pression pour analyseur cellulaire, analyseur cellulaire et procédé d'analyse d'un échantillon cellulaire liquide
CA2987051A1 (fr) 2015-05-29 2016-12-08 Abbvie Inc. Anticorps anti-cd40 et leurs utilisations
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
AU2016321146C1 (en) * 2015-09-08 2021-10-28 Theripion, Inc. ApoA-1 fusion polypeptides and related compositions and methods
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3355921A4 (fr) 2015-09-30 2019-05-22 Janssen Biotech, Inc. Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
EP3362475B1 (fr) 2015-10-12 2023-08-30 Innate Pharma Agents de blocage de cd73
RS60477B1 (sr) 2016-02-10 2020-08-31 Novartis Ag Upotreba inhibitora aktivnosti ili funkcije pi3k za lečenje primarnog sjögren-ovog sindroma
CN108699158B (zh) 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
EP3912681A1 (fr) 2016-03-14 2021-11-24 Orega Biotech Anticorps anti-cd39
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018065552A1 (fr) 2016-10-06 2018-04-12 Innate Pharma Anticorps anti-cd39
WO2018083080A2 (fr) 2016-11-04 2018-05-11 Innate Pharma Ligand de nkp46
WO2018106959A1 (fr) 2016-12-07 2018-06-14 Progenity Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
CA3046548A1 (fr) 2017-01-24 2018-08-02 Innate Pharma Agents de liaison nkp46
EP3577138A1 (fr) 2017-02-06 2019-12-11 Innate Pharma Conjugués médicament anticorps immunomodulateurs se liant à un polypeptide mica humain
CA3051640A1 (fr) 2017-03-16 2018-09-20 Innate Pharma Compositions et methodes pour le traitement du cancer
WO2018182562A1 (fr) * 2017-03-26 2018-10-04 Stafford Vivi Robyn Méthode de traitement d'affections cutanées des paupières
EP4108183A1 (fr) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
WO2018185618A1 (fr) 2017-04-03 2018-10-11 Novartis Ag Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
WO2018217976A1 (fr) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Anticorps monoclonaux antagonistes anti-cd40 et leurs utilisations
EP3630832A1 (fr) * 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Domaines fc d'igg1 modifiés et fusions d'anticorps de domaine anti-cd40 avec ces derniers
TW201902462A (zh) * 2017-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 用於免疫促效劑之新穎投與途徑
US11447545B2 (en) 2017-07-10 2022-09-20 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
CN111263769B (zh) 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体
EP3684813A1 (fr) * 2017-09-19 2020-07-29 MAB Discovery GmbH Anticorps cd40 agonistes
CA3076872A1 (fr) * 2017-11-03 2019-05-09 Novartis Ag Anticorps anti-cd40 destines a etre utilises dans le traitement du syndrome de sjogren
CA3083363A1 (fr) 2017-12-01 2019-06-06 Novartis Ag Anticorps neutralisant les polyomavirus
TW201943731A (zh) 2018-04-13 2019-11-16 瑞士商諾華公司 用於預防移植物排斥之抗cd40抗體
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
WO2019229699A1 (fr) 2018-05-31 2019-12-05 Novartis Ag Anticorps contre l'hépatite b
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
WO2019243252A1 (fr) 2018-06-18 2019-12-26 Innate Pharma Compositions et méthodes pour le traitement du cancer
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
WO2020053742A2 (fr) 2018-09-10 2020-03-19 Novartis Ag Anticorps peptidiques anti-hla-vhb
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
WO2020106757A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique au tube digestif
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
AU2019414793A1 (en) 2018-12-26 2021-06-24 Innate Pharma Compounds and methods for treatment of head and neck cancer
BR112021013174A2 (pt) * 2019-01-11 2021-11-03 Novartis Ag Anticorpos anti-cd40 para uso no tratamento da hidradenite supurativa
JP2022530404A (ja) 2019-04-23 2022-06-29 イナート・ファルマ・ソシエテ・アノニム Ｃｄ７３遮断抗体
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
US20220195061A1 (en) 2019-05-08 2022-06-23 Novartis Ag Anti-cd40 antibodies for use in treatment of tidm and insulitis
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
EA202193345A1 (ru) 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
US20220332836A1 (en) * 2019-09-11 2022-10-20 Novartis Ag A method for preventing human virus associated disorders in patients
AU2020347945A1 (en) 2019-09-18 2022-03-31 Novartis Ag NKG2D fusion proteins and uses thereof
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3173394A1 (fr) 2020-02-27 2021-09-02 Novartis Ag Methodes de production de cellules exprimant un recepteur antigenique chimerique
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
WO2022033978A2 (fr) 2020-08-13 2022-02-17 Innate Pharma Procédés de traitement du cancer utilisant des anticorps anti-cd73
US20230348609A1 (en) * 2020-08-21 2023-11-02 Wuxi Biologics (Shanghai) Co. Ltd. Cd40 agonistic antibody and method of use
EP4199960A2 (fr) 2020-08-21 2023-06-28 Novartis AG Compositions et méthodes pour la génération in vivo de cellules exprimant car
WO2022097065A2 (fr) 2020-11-06 2022-05-12 Novartis Ag Variants fc d'anticorps
WO2022130182A1 (fr) 2020-12-14 2022-06-23 Novartis Ag Agents d'inversion de liaison pour anticorps anti-récepteur 1 du peptide natriurétique (npr1) et leurs utilisations
CA3214085A1 (fr) 2021-03-31 2022-10-06 Darby Rye Schmidt Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
KR20240026185A (ko) * 2021-06-28 2024-02-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
TW202323521A (zh) 2021-08-20 2023-06-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
WO2023025248A1 (fr) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 Composé stéroïde et conjugué de celui-ci
WO2023044048A1 (fr) 2021-09-17 2023-03-23 Novartis Ag Méthodes de prévention du rejet de greffe dans une xénogreffe
CA3232171A1 (fr) 2021-09-24 2023-03-30 Zhenzhen Lu Anticorps anti-cd40 et son utilisation
WO2023052581A1 (fr) 2021-10-01 2023-04-06 Mab Discovery Gmbh Anticorps anti-cd40 agonistes en tant qu'agents immunostimulateurs
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
WO2024056809A1 (fr) 2022-09-15 2024-03-21 Novartis Ag Traitement de troubles auto-immuns à l'aide d'une thérapie par récepteur antigénique chimérique
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766A (en) 1846-09-19 Stbaw-cutter
US106A (en) 1915-08-24 Specipication
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
CA1292686C (fr) 1986-10-27 1991-12-03 Ze'ev Shaked Compositions pharmaceutiques d'interleukine-2 recombinante et procede de fabrication
CA1294215C (fr) 1986-10-27 1992-01-14 Ze'ev Shaked Compositions pharmaceutiques d'interferon beta recombinant et methodes de formulation
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
ES2211884T3 (es) 1993-10-01 2004-07-16 Immunex Corporation Anticuerpos contra el cd40.
ATE267607T1 (de) 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
TR199903141T2 (xx) 1997-06-20 2000-09-21 Biogen, Inc. Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.
PT1224940E (pt) 1997-09-23 2005-01-31 Rentschler Biotech Gmbh Formulacoes liquidas de intrferao beta
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2001034649A2 (fr) 1999-11-09 2001-05-17 Chiron Corporation Compositions et methodes de traitement de maladies auto-immunes et des rejets de greffon
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (fr) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
KR20030031957A (ko) 2000-07-12 2003-04-23 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈 항체 및 면역 조절 항체 관련 적용의 조합을이용한 ｂ 세포 악성종양의 치료
KR20040023565A (ko) 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
AU2002243718B2 (en) 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
ATE507839T1 (de) 2001-04-02 2011-05-15 Genentech Inc Kombinationstherapie
CA2658221C (fr) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-cd40
WO2003029296A1 (fr) 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003045978A2 (fr) 2001-11-26 2003-06-05 Chiron Corporation Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
WO2003074679A2 (fr) * 2002-03-01 2003-09-12 Xencor Optimisation d'anticorps
WO2004071439A2 (fr) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Preparation d'immunoglobuline et son procede de production
EP2236172A1 (fr) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Thérapie combinée avec des anticorps anti-CD20 et anti-CD40 pour le traitment de cancers des cellules B
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP1694360B1 (fr) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Utilisation d'anticorps antagonistes anti-cd40 pour le traitement de maladies autoimmunes et inflammatoires et le rejet d'organes transplantes
WO2005044304A2 (fr) 2003-11-04 2005-05-19 Chiron Corporation Utilisation d'anticorps anti-cd40 antagonistes pour le traitement de la leucemie lymphocytique chronique
EP2301575A1 (fr) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Procédé de thérapie pour tumeurs solides exprimant l'antigène de la surface de cellule CD40
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
AU2004309275B2 (en) * 2003-12-25 2010-12-23 Kyowa Kirin Co., Ltd. Mutants of anti-CD40 antibody
WO2006073443A2 (fr) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
CN101351478A (zh) 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
BRPI0621065A2 (pt) * 2005-12-16 2011-11-29 Genentech Inc anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
NZ572177A (en) * 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
WO2008122007A1 (fr) * 2007-04-02 2008-10-09 Genentech, Inc. Marqueurs biologiques prédictifs de la réaction de la polyarthrite rhumatoïde aux antagonistes de lymphocytes b
AU2008275559B2 (en) * 2007-04-02 2014-04-10 Genentech, Inc. Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
AU2008260498B2 (en) * 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
EP2423228B1 (fr) * 2009-04-20 2015-12-16 Kyowa Hakko Kirin Co., Ltd. Anticorps contenant igg2 ayant une mutation d'acide aminé introduite dans celui-ci
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP2967348B1 (fr) 2013-03-15 2022-03-23 Synaptive Medical Inc. Système de positionnement intelligent

Also Published As

Publication number Publication date
BR112013011644B1 (pt) 2022-02-22
HRP20171084T1 (hr) 2017-10-06
EP3502138A1 (fr) 2019-06-26
HUE034203T2 (en) 2018-01-29
EP3222636A1 (fr) 2017-09-27
ES2911460T3 (es) 2022-05-19
US20140341898A1 (en) 2014-11-20
US9828433B2 (en) 2017-11-28
US11124578B2 (en) 2021-09-21
CU24057B1 (es) 2014-12-26
TW201305208A (zh) 2013-02-01
HRP20220413T1 (hr) 2022-05-27
AR122999A2 (es) 2022-10-19
CA2815921A1 (fr) 2012-05-24
US20160152721A1 (en) 2016-06-02
IL225719A0 (en) 2013-06-27
US20170267772A1 (en) 2017-09-21
SG189928A1 (en) 2013-06-28
EA201390725A1 (ru) 2013-09-30
US8828396B2 (en) 2014-09-09
AR083847A1 (es) 2013-03-27
PT3502138T (pt) 2022-04-06
AU2011331288A1 (en) 2013-05-02
CN105949314A (zh) 2016-09-21
US20180118843A1 (en) 2018-05-03
UA112417C2 (uk) 2016-09-12
EP2640749B1 (fr) 2017-04-19
BR112013011644A2 (pt) 2016-08-02
US9221913B2 (en) 2015-12-29
HUE058015T2 (hu) 2022-06-28
CN105949314B (zh) 2021-04-09
EP3502138B1 (fr) 2022-01-19
PE20140979A1 (es) 2014-08-09
EP3502138B9 (fr) 2022-03-09
US20120121585A1 (en) 2012-05-17
TW201623335A (zh) 2016-07-01
CN103209996A (zh) 2013-07-17
TWI531581B (zh) 2016-05-01
CN103209996B (zh) 2016-07-20
KR101632775B1 (ko) 2016-06-22
RS56153B1 (sr) 2017-11-30
PT2640749T (pt) 2017-07-25
AU2011331288B2 (en) 2014-09-11
UY39292A (es) 2021-07-30
NZ609549A (en) 2015-05-29
JO3266B1 (ar) 2018-09-16
LT2640749T (lt) 2017-07-10
US20200087409A1 (en) 2020-03-19
DK3502138T3 (da) 2022-04-19
JP5782132B2 (ja) 2015-09-24
RS63094B1 (sr) 2022-04-29
EP2640749A1 (fr) 2013-09-25
EP4023676A1 (fr) 2022-07-06
CU20130071A7 (es) 2013-09-27
GT201300128A (es) 2015-06-02
TWI608016B (zh) 2017-12-11
US20220204635A1 (en) 2022-06-30
CA2815921C (fr) 2021-07-06
SI3502138T1 (sl) 2022-05-31
ZA201302532B (en) 2014-09-25
UY33728A (es) 2012-06-29
WO2012065950A1 (fr) 2012-05-24
DK2640749T3 (en) 2017-07-31
PL3502138T3 (pl) 2022-05-02
EA026133B1 (ru) 2017-03-31
IL225719A (en) 2017-09-28
CY1119097T1 (el) 2018-01-10
US9688768B2 (en) 2017-06-27
ES2633817T3 (es) 2017-09-25
US10323096B2 (en) 2019-06-18
MX2013005477A (es) 2013-06-12
MY159316A (en) 2016-12-30
KR20130080856A (ko) 2013-07-15
PL2640749T3 (pl) 2017-09-29
CR20130222A (es) 2013-06-28
JP2014500720A (ja) 2014-01-16
CL2013001124A1 (es) 2014-07-04
MX336633B (es) 2016-01-26
CO6801629A2 (es) 2013-11-29
LT3502138T (lt) 2022-04-11
SI2640749T1 (sl) 2017-07-31

Similar Documents

Publication Publication Date Title
MA34654B1 (fr) Variants silencieux de fc d'anticorps anti-cd40
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA31795B1 (fr) Molécules et méthodes pour moduler un constituant de complément
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA34641B1 (fr) Anticorps anti-il-23
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
MX349463B (es) Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
MA30632B1 (fr) Anticorps humanisé
MA33349B1 (fr) Compositions pharmaceutiques solides et procedes pour leur production
MA35638B1 (fr) 2-thiopyrimidinones
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA33457B1 (fr) L-sérine pour son utilisation en tant que médicament pour prévenir et/ou traiter une réaction inflammatoire de la peau
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
MA20150279A1 (fr) (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2